Bioventus (BVS) Competitors $6.76 +0.11 (+1.65%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$6.80 +0.04 (+0.67%) As of 10/8/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock BVS vs. PRCT, AORT, LMAT, LQDA, ENOV, CDRE, NVCR, CNMD, KMTS, and PLSEShould you be buying Bioventus stock or one of its competitors? The main competitors of Bioventus include PROCEPT BioRobotics (PRCT), Artivion (AORT), LeMaitre Vascular (LMAT), Liquidia Technologies (LQDA), Enovis (ENOV), Cadre (CDRE), NovoCure (NVCR), CONMED (CNMD), Kestra Medical Technologies (KMTS), and Pulse Biosciences (PLSE). These companies are all part of the "medical equipment" industry. Bioventus vs. Its Competitors PROCEPT BioRobotics Artivion LeMaitre Vascular Liquidia Technologies Enovis Cadre NovoCure CONMED Kestra Medical Technologies Pulse Biosciences Bioventus (NYSE:BVS) and PROCEPT BioRobotics (NASDAQ:PRCT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings, analyst recommendations and media sentiment. Which has more risk & volatility, BVS or PRCT? Bioventus has a beta of 0.81, meaning that its stock price is 19% less volatile than the S&P 500. Comparatively, PROCEPT BioRobotics has a beta of 0.99, meaning that its stock price is 1% less volatile than the S&P 500. Does the media refer more to BVS or PRCT? In the previous week, PROCEPT BioRobotics had 3 more articles in the media than Bioventus. MarketBeat recorded 4 mentions for PROCEPT BioRobotics and 1 mentions for Bioventus. Bioventus' average media sentiment score of 1.85 beat PROCEPT BioRobotics' score of 0.31 indicating that Bioventus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bioventus 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive PROCEPT BioRobotics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Is BVS or PRCT more profitable? Bioventus has a net margin of -7.11% compared to PROCEPT BioRobotics' net margin of -30.60%. Bioventus' return on equity of 15.61% beat PROCEPT BioRobotics' return on equity.Company Net Margins Return on Equity Return on Assets Bioventus-7.11% 15.61% 4.01% PROCEPT BioRobotics -30.60%-23.73%-17.34% Which has stronger earnings and valuation, BVS or PRCT? PROCEPT BioRobotics has lower revenue, but higher earnings than Bioventus. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioventus$564.14M0.99-$156.23MN/AN/APROCEPT BioRobotics$274.95M7.03-$91.41M-$1.55-22.42 Do analysts recommend BVS or PRCT? Bioventus currently has a consensus target price of $13.75, indicating a potential upside of 103.40%. PROCEPT BioRobotics has a consensus target price of $70.00, indicating a potential upside of 101.44%. Given Bioventus' stronger consensus rating and higher probable upside, research analysts clearly believe Bioventus is more favorable than PROCEPT BioRobotics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bioventus 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75PROCEPT BioRobotics 1 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.60 Do insiders and institutionals believe in BVS or PRCT? 62.9% of Bioventus shares are owned by institutional investors. Comparatively, 89.5% of PROCEPT BioRobotics shares are owned by institutional investors. 33.0% of Bioventus shares are owned by insiders. Comparatively, 6.6% of PROCEPT BioRobotics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. SummaryBioventus beats PROCEPT BioRobotics on 9 of the 15 factors compared between the two stocks. Get Bioventus News Delivered to You Automatically Sign up to receive the latest news and ratings for BVS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BVS vs. The Competition Export to ExcelMetricBioventusSurgical & medical instruments IndustryMedical SectorNYSE ExchangeMarket Cap$558.91M$68.01M$6.09B$22.02BDividend YieldN/AN/A5.69%3.58%P/E Ratio-11.0810.4785.3529.86Price / Sales0.9933.04539.7865.87Price / Cash12.5818.4137.9224.43Price / Book2.4114.5813.014.64Net Income-$156.23M-$26.69M$3.30B$1.01B7 Day Performance0.75%-0.02%4.34%0.44%1 Month Performance-7.02%-0.22%9.49%3.13%1 Year Performance-41.06%50.20%84.83%15.30% Bioventus Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BVSBioventus3.2314 of 5 stars$6.76+1.7%$13.75+103.4%-41.7%$558.91M$564.14M-11.081,200Positive NewsPRCTPROCEPT BioRobotics2.9278 of 5 stars$36.49-0.5%$70.00+91.8%-53.0%$2.04B$274.95M-23.54430Analyst ForecastAORTArtivion2.9985 of 5 stars$42.03+2.4%$43.13+2.6%+59.6%$1.94B$388.54M-100.061,600Analyst ForecastLMATLeMaitre Vascular3.8648 of 5 stars$85.45+1.5%$97.60+14.2%-2.6%$1.91B$219.86M41.48490Analyst ForecastLQDALiquidia Technologies3.4157 of 5 stars$22.80+4.6%$32.11+40.8%+118.5%$1.88B$14M-13.4150Analyst ForecastENOVEnovis3.754 of 5 stars$30.19+0.7%$51.00+68.9%-18.2%$1.71B$2.11B-2.127,367News CoverageAnalyst ForecastCDRECadre2.1731 of 5 stars$36.06-0.8%$31.50-12.6%-1.3%$1.48B$567.56M38.362,284News CoverageAnalyst ForecastNVCRNovoCure4.1445 of 5 stars$12.92+0.2%$28.79+122.8%-2.1%$1.44B$605.22M-8.281,488Positive NewsAnalyst ForecastCNMDCONMED4.6281 of 5 stars$45.64-0.8%$59.80+31.0%-27.2%$1.42B$1.31B12.933,900Analyst ForecastKMTSKestra Medical Technologies1.1152 of 5 stars$23.41-3.8%$27.33+16.8%N/A$1.25B$66.40M0.00300Analyst ForecastPLSEPulse Biosciences3.193 of 5 stars$17.80+0.2%$22.00+23.6%+26.3%$1.20B$700K-16.95140Analyst Forecast Related Companies and Tools Related Companies PROCEPT BioRobotics Alternatives Artivion Alternatives LeMaitre Vascular Alternatives Liquidia Technologies Alternatives Enovis Alternatives Cadre Alternatives NovoCure Alternatives CONMED Alternatives Kestra Medical Technologies Alternatives Pulse Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:BVS) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioventus Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bioventus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
